RecruitingNot ApplicableNCT06880094

Study of Congenital Orofacial Clefts by Implementing Optical Genome Mapping


Sponsor

Centre Hospitalier Universitaire, Amiens

Enrollment

26 participants

Start Date

Feb 18, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Orofacial clefts, the most common congenital craniofacial malformations, have a complex etiology involving an interaction between genetic and environmental factors. Chromosomal abnormalities, including structural variations, represent a major cause of human pathology. Recently, technological developments and the introduction of next-generation sequencing (NGS) technologies have revolutionized the field of medical genetics. Optical genome mapping (OGM) is an innovative, high-resolution "long read" technique that enables the identification of all classes of chromosomal variation, consisting in the direct visualization of long, labeled DNA molecules throughout the genome. This technology is gradually becoming an essential tool for studying onco-hematology and constitutional genetic pathologies The purpose of this study is to search for structural chromosomal variants (SV) or copy number variants (CNV) not identifiable either by cytogenetic methods nor by "short read" NGS "short read, in individuals with oral-facial clefts with no genetic diagnosis.


Eligibility

Inclusion Criteria3

  • Individuals with syndromic, complex or familial oral-facial clefts
  • With no established genetic diagnosis
  • Followed up at the Amiens-Picardie University Hospital

Exclusion Criteria4

  • genetic diagnosis of oral-facial cleft
  • No health insurance affiliation
  • Patient under guardianship or curatorship, under safeguard of justice or deprived under public law
  • Pregnant, parturient or breast-feeding woman

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICblood withdrawal

blood withdrawal for genetic testing


Locations(1)

CHRU Amiens

Amiens, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06880094


Related Trials